ES2529167T3 - Método para utilizar lípidos neutros para modificar la liberación in vivo desde liposomas multivesiculares - Google Patents

Método para utilizar lípidos neutros para modificar la liberación in vivo desde liposomas multivesiculares Download PDF

Info

Publication number: ES2529167T3
Authority: ES; Spain
Prior art keywords: neutral; modify; lipid; neutral lipids; release
Prior art date: 1997-01-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES98907341.6T

Other languages

English (en)

Spanish (es)

Inventor

Randall C. Willis

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pacira Pharmaceuticals Inc

Original Assignee

Pacira Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-31

Filing date

1998-01-29

Publication date

2015-02-17

1998-01-29 Application filed by Pacira Pharmaceuticals Inc filed Critical Pacira Pharmaceuticals Inc

2015-02-17 Application granted granted Critical

2015-02-17 Publication of ES2529167T3 publication Critical patent/ES2529167T3/es

2018-01-29 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

150000002632 lipids Chemical class 0.000 title abstract 7
230000007935 neutral effect Effects 0.000 title abstract 7
238000001727 in vivo Methods 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 3
239000002502 liposome Substances 0.000 title abstract 2
239000000203 mixture Substances 0.000 abstract 3
SKGWNZXOCSYJQL-BUTYCLJRSA-N 1,2,3-tripalmitoleoylglycerol Chemical compound CCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCC)COC(=O)CCCCCCC\C=C/CCCCCC SKGWNZXOCSYJQL-BUTYCLJRSA-N 0.000 abstract 2
BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 abstract 2
PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 abstract 2
229940117972 triolein Drugs 0.000 abstract 2
SKGWNZXOCSYJQL-UHFFFAOYSA-N tripalmitoleoyl-sn-glycerol Natural products CCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCC)COC(=O)CCCCCCCC=CCCCCCC SKGWNZXOCSYJQL-UHFFFAOYSA-N 0.000 abstract 2
239000004480 active ingredient Substances 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
238000002844 melting Methods 0.000 abstract 1
230000008018 melting Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/829—Liposomes, e.g. encapsulation

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Plant Pathology (AREA)
Dispersion Chemistry (AREA)
Physics & Mathematics (AREA)
Emergency Medicine (AREA)
Biophysics (AREA)
Microbiology (AREA)
Pain & Pain Management (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ES98907341.6T 1997-01-31 1998-01-29 Método para utilizar lípidos neutros para modificar la liberación in vivo desde liposomas multivesiculares Expired - Lifetime ES2529167T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US792566		1997-01-31
US08/792,566 US5891467A (en)	1997-01-31	1997-01-31	Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
PCT/US1998/001636 WO1998033483A1 (fr)	1997-01-31	1998-01-29	Procede servant a utiliser des lipides neutres afin de modifier la liberation in vivo depuis des liposomes a vesicules multiples

Publications (1)

Publication Number	Publication Date
ES2529167T3 true ES2529167T3 (es)	2015-02-17

Family

ID=25157347

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES98907341.6T Expired - Lifetime ES2529167T3 (es)	1997-01-31	1998-01-29	Método para utilizar lípidos neutros para modificar la liberación in vivo desde liposomas multivesiculares

Country Status (12)

Country	Link
US (2)	US5891467A (fr)
EP (2)	EP0971699B1 (fr)
JP (2)	JP3940177B2 (fr)
AU (1)	AU731038B2 (fr)
CA (3)	CA2851502C (fr)
DK (1)	DK0971699T3 (fr)
ES (1)	ES2529167T3 (fr)
IL (1)	IL131012A0 (fr)
NO (2)	NO329401B1 (fr)
NZ (1)	NZ336843A (fr)
PT (1)	PT971699E (fr)
WO (1)	WO1998033483A1 (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5438075A (en)	1993-03-30	1995-08-01	Skubitz; Keith M.	Oral glutamine to reduce stomatitis
CA2304096C (fr) *	1997-09-18	2003-09-09	Pacira Pharmaceuticals, Inc.	Compositions anesthesiques de liposomes a liberation prolongee
AU752802C (en)	1997-11-14	2006-04-13	Pacira Pharmaceuticals, Inc.	Production of multivesicular liposomes
MXPA00006196A (es) *	1998-10-23	2003-07-21	Idea Ag	Metodo para desarrollar, evaluar y utilizar asociaciones de macromoleculas y agregados complejos para obtener mejores tasas de asociacion/desasociacion controlable y carga efectiva.
DE69825495T2 (de)	1998-12-23	2005-07-28	Idea Ag	Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
CA2374003C (fr) *	1999-05-17	2008-02-12	Aesgen, Inc.	Assimilation cellulaire amelioree d'agents bioactifs
NZ515644A (en) *	1999-06-04	2004-12-24	Skyepharma Inc	Oil-core compositions for the sustained release of hydrophobic drugs
WO2001001962A1 (fr)	1999-07-05	2001-01-11	Idea Ag.	Procede d'amelioration du transport a travers des barrieres semi-permeables compatibles
CN1116875C (zh) *	2000-10-19	2003-08-06	南京振中生物工程有限公司	紫杉醇脂质组合物及其制备方法
US20030180348A1 (en) *	2002-03-22	2003-09-25	Levinson R. Saul	Transcellular drug delivery system
US20050169979A1 (en) *	2002-07-03	2005-08-04	Dov Michaeli	Liposomal vaccine
WO2004004687A2 (fr) *	2002-07-03	2004-01-15	Aphton Corporation	Vaccin liposomal
US20040247661A1 (en) *	2002-07-03	2004-12-09	Dov Michaeli	Liposomal vaccine
CA2493764C (fr) *	2002-08-01	2011-05-24	Aesgen, Inc.	Traitement ameliore du cancer avec la glutamine
US20040213837A1 (en) *	2002-08-05	2004-10-28	Sankaram Mantripragada	Oil-core compositions for the sustained release of hydrophobic drugs
US20040105881A1 (en)	2002-10-11	2004-06-03	Gregor Cevc	Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
ITMI20022323A1 (it) *	2002-10-31	2004-05-01	Maria Rosa Gasco	Composizioni farmaceutiche atte al trattamento di malattie oftalmiche.
WO2005023767A2 (fr)	2003-09-10	2005-03-17	Brentwood Equities Ltd.	Diastereoisomeres de 4-aryloxy-3-hydroxypiperidines
ITMI20041151A1 (it) *	2004-06-09	2004-09-09	Maria Rosa Gasco	Nanoparticelle lipidiche come agenti veicolanti per acidi nucleici procedimento per la loro preparazione e loro uso
AU2006339072A1 (en)	2005-03-14	2007-10-25	Board Of Regents Of The University Of Texas System	Bioactive FUS1 peptides and nanoparticle-polypeptide complexes
CA2605068A1 (fr) *	2005-04-15	2006-10-26	The Board Of Regents Of The University Of Texas System	Administration d'arnsi par compositions lipidiques neutres
US20070110674A1 (en) *	2005-07-29	2007-05-17	Yuhong Xu	Sono-active liposomes and lipid particles and use thereof as contrast agents and active-agent delivery systems
US20070154546A1 (en) *	2005-12-30	2007-07-05	Zhang Jack Y	Sustained release pharmaceutical compositions
CA2661302A1 (fr) *	2006-08-16	2008-02-21	Auspex Pharmaceuticals, Inc.	Preparation et utilite d'analgesiques opioides
WO2008109432A2 (fr) *	2007-03-02	2008-09-12	The Board Of Regents Of The University Of Texas System	Ciblage thérapeutique des interleukines utilisant l'arnsi dans des liposomes neutres
US8900627B2 (en) *	2008-06-06	2014-12-02	Mirna Therapeutics, Inc.	Compositions for the in vivo delivery of RNAi agents
EP3000885B1 (fr)	2009-12-18	2018-07-25	Arrowhead Pharmaceuticals, Inc.	Compositions organiques de traitement des pathologies liées à hsf1
US20120296403A1 (en)	2010-02-10	2012-11-22	Novartis Ag	Methods and compounds for muscle growth
US20110250264A1 (en)	2010-04-09	2011-10-13	Pacira Pharmaceuticals, Inc.	Method for formulating large diameter synthetic membrane vesicles
DK2561077T3 (en)	2010-04-23	2016-08-01	Arrowhead Res Corp	Organic compositions for the treatment of beta-ENaC-related diseases
US9770414B2 (en)	2010-05-13	2017-09-26	Pacira Pharmaceuticals, Inc.	Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
JP6194248B2 (ja)	2010-10-28	2017-09-06	パシラファーマシューティカルズインコーポレーテッド	非ステロイド性抗炎症薬の徐放性処方物
BR112013016365A2 (pt)	2010-12-27	2018-06-26	Terumo Corp	composição de lipossoma e processo para produção do mesmo
WO2012109387A1 (fr)	2011-02-08	2012-08-16	Halozyme, Inc.	Composition et formulation lipidique d'une enzyme dégradant le hyaluronane et son utilisation pour le traitement de l'hyperplasie bénigne de la prostate
CA2864394C (fr)	2011-03-02	2021-10-19	Jack Roth	Une methode de prediction d'une reponse a une therapie tusc2
CA3185394A1 (fr)	2011-09-02	2013-03-07	Arrowhead Pharmaceuticals, Inc.	Compositions organiques de traitement de maladies associees a hsf1
GB201119032D0 (en)	2011-11-03	2011-12-14	Isis Innovation	Multisomes: encapsulated droplet networks
EP2802658A2 (fr)	2012-01-09	2014-11-19	Novartis AG	Compositions organiques pour traiter des maladies associées à la bêta-caténine
EA201492004A1 (ru)	2012-05-02	2015-08-31	Новартис Аг	Органические композиции для лечения kras-ассоциированных заболеваний
EP2846773A4 (fr)	2012-05-10	2015-12-30	Painreform Ltd	Préparations de dépôt d'un anesthésiant local et procédés de préparation associés
CN110464709A (zh)	2012-08-10	2019-11-19	德克萨斯州大学系统董事会	用于治疗中风的神经保护性脂质体组合物和方法
GB201219196D0 (en)	2012-10-25	2012-12-12	Isis Innovation	Droplet assembly method
GB201219201D0 (en)	2012-10-25	2012-12-12	Isis Innovation	Hydrogel network
KR102449271B1 (ko)	2012-12-07	2022-09-29	옥스포드 유니버시티 이노베이션 리미티드	3d 프린팅에 의한 비말 어셈블리
CN105247051A (zh)	2013-02-28	2016-01-13	箭头研究公司	治疗epas1相关疾病的有机组合物
AU2014230834B9 (en)	2013-03-14	2017-08-31	Fresenius Kabi Deutschland Gmbh	Injectable morphine formulations
WO2014140097A1 (fr)	2013-03-14	2014-09-18	Becton Dickinson France S.A.S.	Système de conditionnement pour médicaments sensibles à l'oxygène
US9693958B2 (en)	2013-03-15	2017-07-04	Cureport, Inc.	Methods and devices for preparation of lipid nanoparticles
WO2015051135A2 (fr)	2013-10-04	2015-04-09	Novartis Ag	Compositions organiques destinées au traitement de maladies associées à l'hepcidine
EP3736334A1 (fr)	2014-07-16	2020-11-11	Arrowhead Pharmaceuticals, Inc.	Compositions d'arni pour le traitement de pathologies liées à l'apoc3
PT3186281T (pt)	2014-08-28	2019-07-10	Halozyme Inc	Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica
EP3191592A1 (fr)	2014-09-11	2017-07-19	Novartis AG	Inhibition de prmt5 dans le traitement de maladies liées à une déficience en mtap
WO2016089883A1 (fr)	2014-12-01	2016-06-09	Novartis Ag	Compositions et méthodes pour le diagnostic et le traitement du cancer de la prostate
JP6316182B2 (ja)	2014-12-19	2018-04-25	富士フイルム株式会社	リポソームの製造方法及びリポソーム製造装置
EP3302525A2 (fr)	2015-06-05	2018-04-11	Novartis AG	Méthodes et compositions permettant de diagnostiquer, traiter et surveiller le traitement de troubles associés à une déficience en shank3
CN106546705B (zh) *	2015-09-21	2020-03-17	上海复旦张江生物医药股份有限公司	一种脂质体药物体外释放的测试方法
CN106546706B (zh) *	2015-09-21	2020-03-17	上海复旦张江生物医药股份有限公司	pH梯度主动载药法制备的脂质体药物的体外释放测试方法
US10736880B2 (en)	2015-12-18	2020-08-11	The Board Of Regents Of The University Of Texas Systems	Therapeutics for preterm labor management
CN110381929A (zh) *	2016-06-13	2019-10-25	阿森迪亚制药有限责任公司	卡维地洛分散系统的肠胃外缓释传递
WO2018047148A1 (fr)	2016-09-12	2018-03-15	Novartis Ag	Composés pour inhibition du miarn
JP7041136B2 (ja)	2016-10-12	2022-03-23	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	Ｔｕｓｃ２免疫療法のための方法および組成物
EP3535396A1 (fr)	2016-11-01	2019-09-11	Novartis AG	Procédés et compositions pour améliorer l'édition de gènes
EP3541815A4 (fr)	2016-11-18	2020-07-15	Pacira Pharmaceuticals, Inc.	Formulations de liposomes multivésiculaires à microparticules de complexe de méloxicam de zinc et leurs procédés de fabrication
KR102069680B1 (ko) *	2017-03-02	2020-01-23	단디바이오사이언스 주식회사	면역억제인자 제어물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
US11530413B2 (en)	2017-07-21	2022-12-20	Novartis Ag	Compositions and methods to treat cancer
KR20240161202A (ko)	2017-09-11	2024-11-12	애로우헤드 파마슈티컬스 인코포레이티드	아포지단백질 C-III (APOC3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물
AU2018386215B2 (en)	2017-12-15	2024-11-28	Board Of Regents, The University Of Texas System	Methods and compositions for treating cancer using exosomes-associated gene editing
WO2019150309A1 (fr)	2018-02-02	2019-08-08	Hammack Scott	Modulateurs de gpr68 et leurs utilisations pour le traitement et la prévention de maladies
EP3775258A4 (fr)	2018-03-28	2022-01-26	Board of Regents, The University of Texas System	Identification d'altérations épigénétiques dans de l'adn isolé à partir d'exosomes
WO2019213276A1 (fr)	2018-05-02	2019-11-07	Novartis Ag	Régulateurs de cellules souches pluripotentes humaines et leurs utilisations
EP3870700A1 (fr)	2018-10-24	2021-09-01	Codiak BioSciences, Inc.	Procédés d'amélioration de la puissance d'électroporation
SG11202105577TA (en)	2019-01-09	2021-06-29	Arrowhead Pharmaceuticals Inc	Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
US20220136011A1 (en)	2019-02-08	2022-05-05	Board Of Regents, The University Of Texas System	Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
WO2021011299A1 (fr) *	2019-07-12	2021-01-21	Pacira Pharmaceuticals, Inc.	Formulations de liposomes multivésiculaires de dexmédétomidine
CN115996707A (zh)	2020-04-20	2023-04-21	德克萨斯大学系统董事会	生物活性干粉组合物及其制造和使用方法
WO2022040435A1 (fr)	2020-08-19	2022-02-24	The Board Of Regents Of The University Of Texas System	Nanomédicaments pour l'administration ciblée de médicaments et leur utilisation
EP4277933A4 (fr)	2021-01-14	2024-12-11	Senti Biosciences, Inc.	Régulation de charge utile sécrétable
US12151024B2 (en)	2021-01-22	2024-11-26	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en)	2021-01-22	2022-03-22	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en)	2021-01-22	2022-06-14	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en)	2021-01-22	2021-06-15	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
EP4415713A4 (fr)	2021-10-14	2025-08-06	Pacira Pharmaceuticals Inc	Formulations de liposomes multivésiculaires de bupivacaïne et leurs utilisations
US20250303000A1 (en)	2022-05-18	2025-10-02	The Children's Hospital Of Philadelphia	Compositions and methods for inducible alternative splicing regulation of gene expression
CN117731835B (zh) *	2023-12-19	2024-08-02	上海花瓣生物科技有限公司	一种含透明质酸钠、琼脂糖微球注射用凝胶的制备方法
US12251472B1 (en)	2024-05-20	2025-03-18	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US12280149B1 (en)	2024-05-20	2025-04-22	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US12156940B1 (en)	2024-05-20	2024-12-03	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4078052A (en)	1976-06-30	1978-03-07	The United States Of America As Represented By The Secretary Of Health, Education And Welfare	Large unilamellar vesicles (LUV) and method of preparing same
CH624011A5 (fr)	1977-08-05	1981-07-15	Battelle Memorial Institute
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
IT1111367B (it)	1978-11-17	1986-01-13	Serono Ist Farm	Processo per la preparazione estemporanea di liposomi e liposomi cosi' ottenuti
US4310506A (en)	1979-02-22	1982-01-12	California Institute Of Technology	Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
US4394372A (en)	1980-12-22	1983-07-19	The Procter & Gamble Company	Process for making lipid membrane structures
FR2521565B1 (fr)	1982-02-17	1985-07-05	Dior Sa Parfums Christian	Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
US4522803A (en)	1983-02-04	1985-06-11	The Liposome Company, Inc.	Stable plurilamellar vesicles, their preparation and use
US4485054A (en)	1982-10-04	1984-11-27	Lipoderm Pharmaceuticals Limited	Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US5422120A (en) *	1988-05-30	1995-06-06	Depotech Corporation	Heterovesicular liposomes
AU686277B2 (en) *	1993-11-16	1998-02-05	Pacira Pharmaceuticals, Inc.	Vesicles with controlled release of actives
US5993850A (en) *	1994-09-13	1999-11-30	Skyepharma Inc.	Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
CA2181390C (fr) *	1995-07-18	2001-04-24	Pankaj Modi	Formulations a base de phospholipides

1997
- 1997-01-31 US US08/792,566 patent/US5891467A/en not_active Expired - Lifetime
- 1997-11-19 US US08/974,296 patent/US5962016A/en not_active Expired - Lifetime
1998
- 1998-01-29 EP EP98907341.6A patent/EP0971699B1/fr not_active Expired - Lifetime
- 1998-01-29 DK DK98907341.6T patent/DK0971699T3/en active
- 1998-01-29 IL IL13101298A patent/IL131012A0/xx not_active IP Right Cessation
- 1998-01-29 ES ES98907341.6T patent/ES2529167T3/es not_active Expired - Lifetime
- 1998-01-29 CA CA2851502A patent/CA2851502C/fr not_active Expired - Lifetime
- 1998-01-29 NZ NZ336843A patent/NZ336843A/en not_active IP Right Cessation
- 1998-01-29 AU AU63178/98A patent/AU731038B2/en not_active Expired
- 1998-01-29 JP JP53303398A patent/JP3940177B2/ja not_active Expired - Lifetime
- 1998-01-29 WO PCT/US1998/001636 patent/WO1998033483A1/fr not_active Ceased
- 1998-01-29 CA CA002277956A patent/CA2277956C/fr not_active Expired - Lifetime
- 1998-01-29 PT PT98907341T patent/PT971699E/pt unknown
- 1998-01-29 EP EP10183246.7A patent/EP2322143B1/fr not_active Expired - Lifetime
- 1998-01-29 CA CA2692302A patent/CA2692302C/fr not_active Expired - Lifetime
1999
- 1999-07-27 NO NO19993635A patent/NO329401B1/no not_active IP Right Cessation
2004
- 2004-06-04 JP JP2004167412A patent/JP3973646B2/ja not_active Expired - Lifetime
2010
- 2010-03-24 NO NO20100437A patent/NO333827B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP2001505224A (ja)	2001-04-17
AU6317898A (en)	1998-08-25
NO20100437L (no)	1999-09-27
EP0971699A1 (fr)	2000-01-19
CA2692302A1 (fr)	1998-08-06
NO993635D0 (no)	1999-07-27
EP2322143B1 (fr)	2017-01-11
NZ336843A (en)	2001-07-27
JP3940177B2 (ja)	2007-07-04
PT971699E (pt)	2015-02-04
IL131012A0 (en)	2001-01-28
AU731038B2 (en)	2001-03-22
CA2851502A1 (fr)	1998-08-06
EP0971699B1 (fr)	2014-11-26
US5962016A (en)	1999-10-05
EP2322143A1 (fr)	2011-05-18
CA2692302C (fr)	2014-05-13
WO1998033483A1 (fr)	1998-08-06
JP2004262946A (ja)	2004-09-24
CA2277956C (fr)	2007-01-23
CA2851502C (fr)	2016-03-15
EP0971699A4 (fr)	2006-05-24
DK0971699T3 (en)	2015-02-16
US5891467A (en)	1999-04-06
CA2277956A1 (fr)	1998-08-06
NO329401B1 (no)	2010-10-11
JP3973646B2 (ja)	2007-09-12
NO333827B1 (no)	2013-09-23
NO993635L (no)	1999-09-27

Publication	Publication Date	Title
ES2529167T3 (es)	2015-02-17	Método para utilizar lípidos neutros para modificar la liberación in vivo desde liposomas multivesiculares
PT999826E (pt)	2004-09-30	Formulacao auto-emulsionante para compostos lipofilos
BR9810866A (pt)	2000-09-26	Composição farmacêutica em uma forma de formulação auto-emulsificante para compostos lipofìlicos
ES2174080T3 (es)	2002-11-01	Vehiculos de principios activos a base de agentes tensioactivos no ionicos y sus aplicaciones particularmente en los ambitos alimentario, cosmetico y farmaceutico.
PT1093819E (pt)	2006-09-29	Compostos e composicoes para fornecimento de agentes activos
MX9202407A (es)	1992-11-01	Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
ES2126766T3 (es)	1999-04-01	7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
UA74339C2 (uk)	2005-12-15	Форма для введення, що включає інгібітор протонної помпи у вигляді окремих одиниць, та спосіб їх одержання
ES2118677T1 (es)	1998-10-01	Una composicion que comprende un agente activo disuelto en un vehiculo vitrificante y un procedimiento para su preparacion.
MX9207263A (es)	1993-06-01	Sistema para el suministro de una substancia activa para la liberacion sostenida.
ES2145118T3 (es)	2000-07-01	Derivados de acidos grasos y composiciones farmaceuticas que los contienen.
FI940993A0 (fi)	1994-03-02	Salisyylihapon kosmeettinen jakelujärjestelmä ja menetelmä tämän valmistamiseksi
DK1073415T3 (da)	2006-03-06	Gelerbare farmaceutiske sammensætninger
ES2178479T3 (es)	2002-12-16	Concentrado de principio activo con formoterol, apto para el almacenamiento.
ES2042700T3 (es)	1993-12-16	Composiciones farmaceuticas con liberacion controlada, y metodo para su preparacion.
ES2092386T3 (es)	1996-11-16	Composicion para combatir el envejecimiento, que actua sobre las capas superficiales y profundas de la piel, su utilizacion.
BR9912285B1 (pt)	2009-12-01	processos para a preparação de uma mistura de ésteres alquila c1-4 de ácido graxo dimérico e trimérico, e, misturas de ésteres alquila c1-4 de ácido graxo dimérico e trimérico obtidas pelos referidos processos.
BR9814756A (pt)	2000-10-03	Composição sólida seca para liberação de droga, processo para a preparação da mesma, uso de um grande número de pequenas esferas que contêm uma matriz polimérica composta de um polietileno glicol ou de uma mistura de polietileno glicóis
AR018357A1 (es)	2001-11-14	Acido petroselinico en una composicion y en un metodo para reducir o eliminar la irritacion o la picazon de la piel inducida por los alfa-hidroxiacidos
AR018607A1 (es)	2001-11-28	Preparacion farmaceutica que en calidad de ingrediente activo contiene levotiroxina sodica, y un procedimiento para su preparacion
MY138975A (en)	2009-08-28	Novel preparation and administration form comprising an acid-labile active compound
KR960021018A (ko)	1996-07-18	약제학적 조성물
ES2108698T3 (es)	1998-01-01	Liposomas exentos de sustancias activas, para el tratamiento de aterosclerosis.
ES2163147T3 (es)	2002-01-16	Perfeccionamientos de agentes antimicrobianos de accion prolongada o relativos a los mismos.
PE97199A1 (es)	1999-10-05	Composiciones solubilizadas de sertralina